Proscia Earns SOC 2 Type II Certification for Digital Pathology Platform
The compliance milestone adds to the company's existing ISO certifications as enterprise deployments accelerate across pharmaceutical and diagnostic laboratory customers.
Category: Compliance
Compliance
Latest
Compliance
Latest
AMP Celebrates Decision to Vacate FDA Rule on LDT Regs
A federal court ruled in favor of AMP, striking down the FDA’s attempt to regulate laboratory-developed tests (LDTs) as medical devices.
Compliance
Latest
ADLM Says FDA’s LDT Final Rule Will Impede Fight Against Drug Epidemic
An ADLM survey found that the FDA’s LDT final rule will likely reduce patient access to crucial tests, despite exemptions to mitigate this.
CMS and CDC Issue Final Rulemaking Updating CLIA Fees
CMS and the CDC issued Final Rulemaking [CMS-3326-F] to update the CLIA fees and clarify the CLIA fee regulations.
Read More
FDA Takes Shot Across the Bow with LDT Rulemaking
The FDA has issued proposed LDT rulemaking. Laboratories have an opportunity to make comments before it becomes official.
Read More
HHS OIG: Labs with Questionably High Billing for Add-On Tests Warrant Further Scrutiny
Certain labs billed Medicare Part B for questionably high levels of add-on tests alongside COVID-19 tests in 2020.
Read More
AACC Statement on Exclusion of VALID Act from Omnibus Bill
AACC issued a statement supporting the U.S. Congress’ exclusion of the VALID Act from its 2023 Omnibus Bill.
Read More
AMP Commends Congress for Nixing VALID Act
The Association of Medical Pathology (AMP) applauded Congress for not including the VALID Act in the Consolidated Appropriations Act of 2023.
Read More
AACC Urges Cutting VALID Act to Preserve Patient Access to LDTs
The AACC is urging clinical lab professionals to write to their legislators to keep the VALID Act out of a Fiscal Year 2023 budget agreement.
Read More
Stop the VALID Act, AMP Urges
AMP is urging medical organizations to contact their elected officials to remove the VALID Act from a 2023 “omnibus” appropriations bill.
Read More
FDA Updates COVID-19 Test Policy
The FDA has updated its COVID-19 test policy to ensure continued access to tests, transitioning traditional premarket review pathways.
Read More
CMS Proposes Rule to Update CLIA Fees & Regulations
The Centers for Medicare & Medicaid Services issued a proposed rule that would update the CLIA 1988 fee regulations.
Read More
Theranos Whistleblowers to Give Fireside Chat at AACC 2022
Erika Cheung and Tyler Shultz—two of the key Theranos whistleblowers—will speak in a special fireside chat at AACC 2022.
Read More
Medical & Patient Communities Urge Congress to Stop VALID Act
The AACC joins more than 100 other organizations that have expressed concerns about the Senate HELP committee rushing to pass the VALID Act.
Read More
Do We Really Need VALID Act Regulations?
In CLP’s July cover story, we’re examining how the proposed VALID regulations will affect the laboratory industry and society as a whole.
Read More
Fast Facts: Your Guide to the VALID Act
The bipartisan VALID Act would implement a risk-based review system for all diagnostic tests, including LDTs, under the FDA.
Read More
Do Laboratory-Developed Tests Have a Future?
As the bipartisan VALID Act moves closer to a vote, the potential regulation could impact the future of laboratory-developed tests (LDTs).
Read More
CAP Files Amicus Brief in Support of No Surprises Act Lawsuit
The College of American Pathologists warns the No Surprises Act will further drive more physicians out of their patients’ health plan networks.
Read More